Just as it was 2 years ago, almost all panellists (98.5%) endorsed neoadjuvant systemic treatment for patients with stage 2 or stage 3 triple-negative breast cancer, or with Her2-positive breast cancer. In addition, the panel this year voted about which type of neoadjuvant should be preferred in some specified subtypes of breast cancer. For example, in case of a postmenopausal patient with a luminal A subtype based on immunohistochemistry (or equivalent based on gene expression testing), 81% of the panellists preferred endocrine neoadjuvant therapy over neoadjuvant chemotherapy. This opinion means a clear shift in advantage of neoadjuvant endocrine therapy. Asked for their opinion on the appropriate duration of the endocrine neoadjuvant therapy in postmenopausal patients with a luminal A type tumour, 47% of the panellists preferred to continue endocrine neoadjuvant therapy until optimal reduction in tumour size is reached however long it takes, while 33% of the panellists preferred 6 month of endocrine neoadjuvant therapy.
There was no consensus at all on the issue of the use of a platinum-based regimen – in addition to an anthracycline/taxane based regimen – as neoadjuvant chemotherapy in patients with triple-negative breast cancer; 57% of the panellists voted against a platinum-based regimen, 35% agreed with a platinum-based regimen. On the other hand, platinum-based neoadjuvant chemotherapy was endorsed by 67% of the panellists for a patient with triple-negative breast cancer and a BRCA mutation. This prompted one of the panellists to say this is not in line with the scientific data showing that non-BRCA mutation carriers benefit most from platinum because BRCA mutation carriers are so chemosensitive that the addition of platinum on top of anthracycline/taxane does not add much extra benefit.
« Updated interim results of phase 2 trial of pembrolizumab for high-risk NMIBC unresponsive to BCG Next Article
Gene expression signatures »
Table of Contents: BCC 2019
St. Gallen Consensus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.